Ken Griffin Erasca, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.17 - $3.28 $15,190 - $22,960	7,000 Added 225.81%	10,100 $27,000
Q2 2024 Aug 14, 2024	SELL	$1.79 - $2.63 $7,160 - $10,520	-4,000 Reduced 56.34%	3,100 $7,000
Q1 2024 May 15, 2024	BUY	$1.67 - $2.55 $4,509 - $6,884	2,700 Added 61.36%	7,100 $14,000
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.49 $6,680 - $9,960	4,000 Added 1000.0%	4,400 $9,000
Q3 2023 Nov 14, 2023	BUY	$1.97 - $2.91 $394 - $582	200 Added 100.0%	400 $0
Q2 2023 Aug 14, 2023	SELL	$2.57 - $3.3 $6,682 - $8,580	-2,600 Reduced 92.86%	200 $0
Q1 2023 May 15, 2023	BUY	$2.74 - $4.44 $2,740 - $4,440	1,000 Added 55.56%	2,800 $8,000
Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $7,002 - $15,426	1,800 New	1,800 $7,000

140

229M

28.7K

117K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $310M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.